Methods for treating eye disorders

Abstract

The present invention provides methods of treating an eye disorder. The methods comprise a step of locally administering a Clostridial toxin to the eye of a patient to treat the disorder. The eye disorder may be associated with an inflammation of the eye, including for example, bacterial conjunctivitis, fungal conjunctivitis, viral conjunctivitis, uveitis, keratic precipitates, macular edema, and inflammation response after intra-ocular lens implantation. The Clostridial toxin may be produced by a Clostridial beratti, a Clostridia butyricum, a Clostridial tetani bacterium and/or a Clostridial botulinum.

1 . A method for treating an eye disorder comprising:
 administering an ophthalmic composition to a cornea of a mammal to treat the eye disorder, wherein the ophthalmic composition is a solution and includes an ophthalmically acceptable carrier, a Clostridial toxin in an amount effective to treat the eye disorder when the composition is administered to an eye and a polyanionic component in amount effective to provide lubrication to the eye, thereby treating the eye disorder.   
   
   
       2 . The method of  claim 1  wherein the ophthalmic composition includes a vasoconstrictor. 
   
   
       3 . The method of  claim 1  wherein the eye disorder is associated with an inflammation of the eye. 
   
   
       4 . The method of  claim 1  wherein the eye disorder is bacterial conjunctivitis, fungal conjunctivitis, viral conjunctivitis, uveitis, keratic precipitates, macular edema, or inflammation response after intra-ocular lens implantation. 
   
   
       5 . The method of  claim 1  wherein the eye disorder is conjunctivitis. 
   
   
       6 . The method of  claim 1  wherein the Clostridial toxin is administered topically to the cornea. 
   
   
       7 . The method of  claim 1  wherein the Clostridial toxin is produced by Clostridial beratti, Clostridia butyricum, Clostridial tetani bacterium or Clostridial botulinum. 
   
   
       8 . The method of  claim 1  wherein Clostridial toxin is a  botulinum  toxin selected from the group consisting of  botulinum  types A, B, C 1 , D, E, F, G and mixtures thereof. 
   
   
       9 . The method of  claim 1  wherein the Clostridial toxin is  botulinum  toxin type A. 
   
   
       10 . The method of  claim 8  wherein the eye disorder is associated with an inflammation of the eye. 
   
   
       11 . The method of  claim 8  wherein the eye disorder is bacterial conjunctivitis, fungal conjunctivitis, viral conjunctivitis, uveitis, keratic precipitates, macular edema, and inflammation response after intra-ocular lens implantation. 
   
   
       12 . The method of  claim 8  wherein the eye disorder is conjunctivitis. 
   
   
       13 . The method of  claim 8  wherein the Clostridial toxin is administered topically to the cornea. 
   
   
       14 . The method of  claim 8  wherein the Clostridial toxin is administered in conjunction with a vasoconstrictor.